"You can have the fanciest ideas and molecules, but if you can't get them into the cell, they are of no use.”
- Matthew Porteus, co-founder, crispr therapeutics
Ligandal combines targeting peptides with gene therapy.
THE PROBLEMCRISPR, TALEN, mRNA, DNA and related genome engineering tools do not have effective delivery systems for most addressable cells, tissues and organs. Electroporation and viruses are not sufficient.
|
THE SOLUTIONLigandal maps the cell surface proteome of targeted cells, creating customized peptide targeting ligands that form into nanoparticles. We do this in hours, not months or years.
|
The visionLigandal will make gene therapy predictable, safe and rapid. We aim to provide manufacturing and supply chain services for the industry at large, while creating high-value applications for preclinical escalation and partnering.
|
